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Role of the complement membrane attack complex (C5b-9) in mediat-
ing experimental mesangioproliferative glomerulonephritis. Previous
studies have demonstrated that most pathologic changes in the anti-
thymocyte serum (ATS) model of mesangioproliferative glomerulonephri-
tis are complement-dependent. These include mesangiolysis, glomerular
platelet infiltration, mesangial cell proliferation, mesangial cell production
of growth factors and phenotypic change to express a-actin, glomerular
macrophage infiltrate, mesangial matrix expansion, and proteinuria. The
mechanism by which complement mediates these effects has not been
defined. Because neutrophils do not participate in the ATS model, we
hypothesized that the complement effects observed are consequent to
glomerular cell insertion of the C5b-9 membrane attack complex of
complement. This hypothesis was tested utilizing PVG rats which exhibit
an absence of C6 inherited in an autosomal recessive pattern. C6 deficient
(C—) PVG rat serum activated by zymosan produced normal amounts of
C5a compared to normocomplementemic (C+) PVG rat controls but no
C5b-9. When ATS was induced, C— PVG rats had a significant and
marked reduction in mesangiolysis, platelet infiltration, mesangial cell
proliferation, o-actin expression, macrophage infiltration, collagen IV
deposition, and proteinuria compared to C+ controls. The reduction in
each of these parameters was comparable to that achieved by systemic
complement depletion of C+ PVG rats with cobra venom factor. These
findings establish the role of C5b-9 in mediating each of the complement-
dependent features of the ATS model and indicate that C5b-9 accounts
for all of the complement-mediated effects observed. This study provides
the first documentation of a functional role for C5b-9 in mediating a
non-membranous inflammatory type of glomerular injury in vivo.
Mesangial cell proliferation is a common cellular response to a
variety of different types of glomerular injury in animal models
and in humans [1, 2]. Considerable evidence now suggests that
proliferation of mesangial cells may be central to the subsequent
increase in mesangial matrix and development of glomeruloscle-
rosis [reviewed in 3]. The most extensively studied model of
mesangioproliferative glomerulonephritis is the anti-thymocyte
serum (ATS) model in rats induced by injection of antibody to the
Thy 1.1 antigen expressed on the plasma membrane of mesangial
cells [4]. Recent studies in this model have defined the role of
growth factors including PDGF and bFGF in mesangial cell
proliferation and of TGF/3 in the development of glomeruloscie-
rosis [5—9].
Early studies of the ATS model demonstrated that glomerular
injury including mesangial cell proliferation and proteinuria were
complement-dependent but neutrophil-independent [10]. Subse-
quent studies have confirmed and extended these observations to
document that systemic complement depletion reduces mesangi-
olysis, mesangial cell proliferation, and glomerular platelet and
macrophage influx [11, 12]. Complement depletion also abrogates
increases in PDGF, PDGF receptor, bFGF and extracellular
matrix in this model [5—7, 13]. However, the mechanism of the
complement effect has not been defined.
Nephritogenic consequences of complement activation include
generation of chemotactic factors such as C5a and formation of
the C5b-9 membrane attack complex [14]. C5a is generally
regarded as the principal mediator of lesions involving circulating
inflammatory cells, while C5b-9 has been implicated primarily in
causing proteinuria without inflammatory cells in models of
membranous nephropathy [14]. However, C5b-9 can stimulate
production of multiple inflammatory mediators by resident gb-
merular cells [15—171. Because several inflammatory cellular
processes in the ATS model are complement-dependent and
neutrophils are not present, we hypothesized that these events
may instead be C5b-9 mediated. Our studies, utilizing a C6
deficient strain of PVG rat, implicate C5b-9 for the first time in
mediating inflammatory changes in a model of immune glomer-
ular disease.
Methods
Experimental animals
Three month old male PVG rats weighing 250 —300 grams were
obtained from two separate vendors. PVG rats with normal
complement activity were obtained from Harlan Sprague-Dawley
(Cambridge, UK). Age and sex matched complement deficient
PVG rats were obtained from Bantin and Kingman Universal
(Edmonds, WA). All rats were housed in metabolic cages in an
accredited animal facility with free access to normal rat chow and
water.
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Complement measurements
In order to establish the complement status of PVG rats being
studied, the hemolytic activity in serum from each rat was
measured by a standard CH0 assay [18].
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Individual complement components. In order to determine the
activity of the nine individual complement components in PVG
serum, tube assays developed by Diamedix Corp. (Miami, FL)
were utilized [18, 19]. C3, C5, C6 and C7 were measured using
sheep erythrocytes sensitized by the 7s IgG fraction of antibodies
to sheep erythrocytes and exposed to predetermined concentra-
tions of guinea pig Cl and human C4 (EAClgp4hu). Serial
dilutions of serum (1:50 to 1:8 X i0 depending on the component
being measured) from PVG rats were made in 0.2% gelatin
veronal buffer containing 0.3 m calcium chloride and 2 mrvt
magnesium chloride and 2.5% dextrose (GGVB+ +) and mixed
with 0.1 ml EAClgp4hu cells (5 >< IO cells/mi) along with 0.05 ml
purified human complement components C2 (50 U/mI), C3 (100
U/mi), C5 (50 U/mI), C6 (50 U/mi) and/or C7 (50 U/mI) diluted in
GGVB+ +, omitting the component to be measured. After incu-
bating at 30°C for 30 minutes, in order for C7 to assemble on the
erythrocytes, 0.05 ml guinea pig C8 (100 U/mi) and C9 (50 U/ml)
in GGVB++ were added. The cells were incubated for an
additional 60 minutes at 37°C in order for cell lysis to occur.
Unlysed cells were removed by centrifugation and the optical
density of the supernatants was measured at 415 nm. Sera
obtained from PVG rats with normal CH50 levels (C+) were
compared with sera from PVG rats with low CH5() levels (C—),
and results are expressed as a percentage of the hemolysis from
C+ serum.
C8 and C9 were measured in much the same way as above.
EAClgp4hu cells (0.1 ml at 5 X i0 cells/mi in GGVB++) were
mixed with 0.05 ml of human components C2, C3, CS, C6 and C7
(same concentrations as above) and incubated at 30°C for 30
minutes in order for Cl through C7 to assemble on the erythro-
cytes. Serial dilutions of PVG serum in GGVB+ + (0.05 ml of 5
X i0 to 8 x 106 for C8 and I x i0 to 1.6 x i0 for C9) were then
added, with either human C8 (100 U/mI) or C9 (50 U/mI), leaving
out the component to be measured. The erythrocytes were then
incubated at 37°C for an additional 60 minutes in order for lysis to
occur. Unlysed cells were removed and the optical density of the
supernatants was measured as above.
Cl and C4 were measured using similar assays. Cl activity was
measured using sensitized sheep erythrocytes containing human
C4 (EAChu4). PVG serum (0.05 ml diluted from 6 X i03 through
9.6 x i0 in GGVB+ +) and 0.05 ml of EAC4hu cells (5 X i07
cells/mi in GGVB+ +) were mixed and incubated at 30°C for 20
minutes in order for Cl from the serum to bind. Purified human
C2 (0.05 ml at 50 U/mi) was then added to the cells and incubated
an additional 10 minutes at 30°C. Guinea pig whole complement
(0.05 ml diluted 1:12 in 40 mvi EDTA) was then added to the cells
along with an additional 0.05 ml of 40 mi EDTA. EDTA was
added to bind Ca2 and Mg2* in the GGVB++, which prevents
classical pathway components CI, C2 and C4 from binding. Cells
were incubated at 37°C for 60 minutes. Unlysed cells were
removed by centrifugation, and supernatants were read at 415 nm.
C4 activity was measured using the same procedure, except sheep
erythrocytes containing guinea pig Cl (EACgp1) were used, and
serum was diluted 1:250 through 1:4 X iOfl.
C2 activity was measured in C+ and C— PVG serum by
preparing serial dilutions of serum (1:50 to 1:800) and mixing 0.05
ml with 0.1 ml of EAClgp4hu cells (5 x 108 cells/mI). Cells were
incubated at 30°C for 5 minutes, in order for C2 to bind. Guinea
pig whole complement (0.05 ml of a 1:12.5 dilution in 40 m'vi
EDTA) was then added along with 0.05 ml 40 mi EDTA, and
cells were incubated an additional 60 minutes at 37°C. Unlysed
cells were removed as above, and optical density of the superna-
tants was measured at 415 nm.
Additional measurements were made of CS activity using
higher concentrations of human C6 (Cal Biochem, San Diego,
CA) in the assay, to compensate for the complete deficiency of C6
activity in the C— animals. Results seen in this assay were similar
to the results from the CS assays using the normal concentration
of C6.
In measurements of individual complement components, serum
from five PVG rats that were complement deficient as judged by
CH50 titer was compared with a pooi of serum obtained from five
PVG rats with normal CH5() levels. Measurements of CS levels
were also conducted on 30 individual complement deficient
animals. In addition to the standard hemolytic assay, hemolytic
assays for CS were also carried out in the presence of up to a
fourfold excess of added C6 and also utilizing CS deficient human
serum (Quidel, San Diego, CA) as a C6 source. Results of the
complement component assays are expressed as a percentage of
the normal PVG pool. C5 levels were also assessed by immuno-
blotting utilizing a cross-reactive antibody to human CS (Dako,
Roskilde, Denmark). Immunoblots were quantified with a digi-
tized image analysis system.
C6 protein levels were also assessed in PVG rat serum by
immunoblotting using a polyclonal antibody to human C6 cross-
reactive with rat C6 (gift of Dr. 0. Gotze, Gottingen, Germany) as
well as a monoclonal antibody to rat C6 (3G11) described
elsewhere [20]. In some studies, PVG serum was compared with a
pooi of fresh normal serum obtained from age, sex and weight
matched Sprague-Dawley rats (Simonson Laboratories).
An ELISA assay for rat C6 was also developed utilizing the
polyclonal anti-human C6 as the capturing antibody and a biotin-
ylated version of the same antibody as the detecting antibody
followed by streptavidin-peroxidase utilizing protocols described
elsewhere [20].
C5a generation. CSa generation was measured in duplicate in
zymosan activated sera from two C— and two C+ PVG rats using
a Boyden chamber assay and human neutrophils as described
elsewhere [211. Serial dilutions from 1:10 to 1:320 were assayed.
C5b-9 complex generation. Finally, to assess the ability of PVG
rats to generate C5b-9 complexes 50 p.! of C+ PVG, C— PVG or
C— PVG serum supplemented with human C6 (50 p.g/ml) was
further supplemented with 0.5 p.g of human C8 labeled with 1251
using Bolton-Hunter reagent (1 p.g C8 corresponded to approxi-
mately 0.7 iCi) and inulin (10 mg/mI). After incubation at 37°C
for one hour, inulin was removed by centrifugation (10 mm,
100,000 g), and the supernatants were separated by sucrose-
density centrifugation (5 to 40% sucrose in phosphate-buffered
saline) for 16 hours at 30,000 rpm using a swing-out rotor SW 60
(Beckman Instruments, Munich, Germany). The samples were
harvested in 0.5 ml aliquots and radioactivity measured. For
control purposes, 125J C8 alone or in the presence of preformed
human C5b6 and C7 and C9 (1 p.g each) was added to parallel
tubes.
Induction of experimental mesangioproliferative glomerulonephritis
and experimental design
The ATS model was induced by a single i.v. injection of 1.0
ml/100 g of goat anti-rat Thy I antiserum as described in detail
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elsewhere [5—9]. These groups of animals were studied: Group A
(N — 6) were normocomplementemic PVG (C+ PVG) rats given
ATS; Group B (N = 6)were complement deficient PVG rats (C—
PVG) given ATS; and Group C (N = 6) were normocomple-
mentemic PVG rats given ATS and systemically complement
depleted (C + PVG/CVF) by administration of cobra venom
factor. Urine protein excretion was measured from zero to 24
hours in metabolic cages with free access to food and water.
Biopsies were performed under ether anesthesia 24 hours and five
days after disease induction and examined by light, immunofluo-
rescence, and electron microscopy as described below. CH50
measurements were performed before disease induction and
again at day five.
Complement depletion
C+ PVG rats in group C were depleted of C3 with cobra venom
factor (CVF; naja naja kauthia, Diamedix). Rats were injected
with 30 U i.p. every eight hours on the day prior to disease
induction and then with 30 U twice daily on day zero and one, 50
U twice daily on day two, 70 U twice daily on day three, and 90 U
twice daily on day four prior to sacrifice on day five.
Renal morphology
Light microscopy. Tissue for light microscopy and immunoper-
oxidase staining was fixed in methyl Carnoy's solution and em-
bedded in paraffin. Four micron sections were stained with
periodic acid-Schiff (PAS) and counterstained with hematoxylin.
Immunocytochemistiy. Four micron sections of methyl Carnoys
fixed biopsy tissue were stained by an indirect immunoperoxidase
technique. Antibodies used included:
19A2 (Coulter, Hialeah, FL), a murine monoclonal 1gM anti-
body against human PCNA, which is expressed by actively
proliferating cells [22]
ED-I (Bioproducts for Science, Indianapolis, IN), a murine
monoclonal IgG to a cytoplasmic antigen present in rat
monocytes, macrophages, and dendritic cells [23]
RP-3 (gift of F. Sendo, Yamagato, Japan) a murine monoclonal
IgG antibody to rat neutrophils [24]
PL-1, a murine monoclonal antibody against rat platelets (gift
of W.W. Bakker, Groningen, The Netherlands) [25]
A murine monoclonal antibody to an NH2-terminal synthetic
decapeptide of alpha-smooth muscle actin (gift of G. Gabbi-
ani, Geneva, Switzerland) [26]
A biotinylated IgG fraction of polyclonal goat anti-mouse type
IV collagen (Southern Biotech, Birmingham, AL)
Macrophages, proliferating cells, and neutrophils are reported
as the mean number of cells per glomerulus positively stained by
the respective antibodies as reported elsewhere [5, 11, 13].
Platelet and alpha-smooth muscle actin staining was quantitated
by counting the mean number of quadrants of the glomerulus
which stained positively, as reported elsewhere [27].
Immunofluorescence. Six micron sections of frozen tissue were
stained with FITC conjugated antibodies to goat IgG (Cappel,
Organan Teknika Corp., Durham, NC), human C3d (Dako Corp.,
Carperteria, CA) [28], and a biotinylated anti-rat C5b-9 corn-
plexed to a FITC-bound streptavidin peroxidase system [20, 29].
Glomeruli were graded 0 to 4 based on the intensity of staining.
To further assess the possible effects of reduced levels of C2 in
C— PVG rats, deposition of C3d was quantitated by confocal laser
Table 1. Levels of individual rat complement components in pooled
sera from five C— PVG rats expressed as a percentage of levels in a
pool of five age and sex matched C+ PVG controls
Complement
measurement Present study Leenaerts et al [31]
CH50 <1% <1%
AP5O ND 2.2
Clq ND 88Cl 130 70
C4 60 81
C2 15 ND
C3 80 95
C5" 20 13.5 88
C6 <1 <1
C7 148 70
C8 106 ND
C9 96 ND
D ND 96
B ND 100
H ND 105
C5 assays were done on 30 individual C— PVG rats compared to a pool
of C+ PVG rat serum. Abbreviation ND is not detectable.
a Data are mean SD
microscopy. Four micromolar sections of frozen kidney were
stained for rat C3d as described above. Sections were then
scanned by confocal microscopy using an ACSA Ultima Interac-
tive Laser Cytometer (Meridian Instruments, Okemos, Michigan,
USA), which permits quantitative analysis of fluorescence inten-
sity. An image field of 3.2 mm2 was scanned for each section;
where less than 15 glomeruli were present two fields were
scanned. Using the Meridian image analysis system, the fluores-
cence intensity over individual glomeruli was then analyzed. Data
from a minimum of 13 individual glomeruli per animal were
averaged. Results are expressed as the mean standard error of
average fluorescence units emitted per glomerulus.
Electron microscopy. Portions of biopsy specimens were fixed in
1/2 strength Karnovsky's solution and processed as previously
described [27]. Thin sections were mounted on coated nickel grids
and stained with osmium followed by uranyl acetate. Sections
were examined using a Phillips 410 electron microscope.
Other variables measured. Urine was collected in all animals on
the day following induction of disease and protein content was
measured by a sulfosalicylic acid method [30]. Serum collected
prior to disease induction and at the time of sacrifice was assayed
for CH50 levels.
Statistical analysis. Results are presented as the mean stan-
dard error unless otherwise noted. Comparisons between C+
PVG and C— PVG or C+ PVG/CVF animals were done by
ANOVA and two-tailed unpaired Student's t-test or Mann Whit-
ney test, as appropriate [31]. Statistical significance was defined as
P < 0.05.
Results
Complement measurements
The values for individual complement components in C— PVG
rats as a percentage of levels in C+ PVG rats are given in Table
1. C— PVG rats had no detectable C6 by functional assay. C6 was
also undetectable in C— PVG rats by both immunoblotting and
ELISA assays utilizing a monoclonal antibody specific for rat C6.
All other individual complement components tested were within
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Table 2. Summary of results on day one or five in C+ PVG rats, C—
PVG rats, and C+ PVG rats complement-depleted with CVF
Variables
measured Day C+ PVG C— PVG C+ PVG/CVF
CH50%C+PVG 1
5
100
100
<1%
<1%
<1%
14±8.7
Urine protein 1 32 15 15 6 19 7U
mg/day
Glomerular 1 52 5.6 51 4.2 53 1.8
cellularity cells!
glom
Cell proliferation 5 3.0 0.4 0.53 3 0.21 OP
PCNA + cells!
glom
Alpha-aeOn 5 2.6 0.2 0.23 0.1 0.9 0.5a
(0-4+)
Platelets 1 8.8 2.0 1.7 0.6 1.6 0.5a
celts/glom
Macrophages 1 6.0 0.6 1.1 0.2 0.88 0.04k'
EDI cells/glom
Neutrophils RP3 1 0.0 0.0 0.0
celts/glom
Collagen IV (1—
5
5
0.0
2.6 0.63
0.0
1.4 0.69a
0.0
0.17 0.62
4+)
Immunofluorescence
Goat IgG (0— 1 4+ 4+ 4+
4+)
C3d (0—4+)
5
5
2+
3+
3+
3+
3+
0.5
C5b-9 (0—4+) 5 2+ 0 0
Values are mean SE.P < 0.05 vs. C+ PVG
the normal range (>50% of a normal pool) except for C5 (20%)
and C2 (15%) (Table 1). CH50 levels in rats treated with cobra
venom factor were less than 1% of normal on day one and less
than 15% of normal on day five (Table 2).
To further assess the significance of the reduced C2 levels in
mediating the ATS lesion, rat C3d deposits in glomeruli were
quantitated by confocal laser microscopy at day five. The results
demonstrated no significant reduction in glomerular C3d deposi-
tion in C— PVG rats compared to controls (mean 1410 296 SD
fluorescent units, N = 7 vs. 1742 259 units, N = 8; P > 0.05)
suggesting equivalent C3 activation in both groups. CVF treat-
ment did significantly reduce glomerular C3d deposits (767 40,
P < 0.01).
To further assess the apparent deficiency in CS by standard
hemolytic assay, hemolytic assays were repeated with increased
quantities of human C6 added (up to a fourfold excess) and with
CS deficient human serum as a C6 source with similar results.
Both assays gave CS values of about 20% of a C+ PVG pool.
However, immunoblotting of CS using a cross-reactive antibody to
human CS demonstrated similar or greater quantities of CS
protein in C— PVG rats compared to C+ controls (data not
shown). When CSa generation was measured in C+ and C— PVG
serum, no significant difference between C— and C+ serum in
chemotaxis index or leading front could be demonstrated at any
dilution tested (Table 3).
Finally, the ability of C— PVG serum to generate CSb-9
complexes following vigorous alternative complement pathway
activation with inulin was assessed by measuring incorporation of
1251-Iabeled C8 into CSb-9. In these studies, C6 was repleated to
Table 3. Results of measurements of C5a generation in a Boyden
chamber assay expressed as chemotaxis index and leading front at
different dilutions of C+ and C— PVG serum
Group/dilution Chemotaxis index Leading front pm
C+ PVG
1:10 67 170
1:20 68 160
1:40 56 160
1:80 25 88
1:160 22 70
1:320 20 68
C- PVG
1:10 72 160
1:20 66 185
1:40 58 160
1:80 23 88
1:160 27 92
1:320 24 91
Human serum (1:20) 42 130
Medium alone 20 63
Two samples were studied in duplicate for each group. No significant
differences between C+ and C— PVG sera were detected at any dilution.
Values are means of duplicate samples.
a level of SO g/ml utilizing purified human C6. In C+ PVG sera,
19% of the radiolabeled C8 appeared in the 19S fraction corre-
sponding to the sedimentation of C5b-9 formed from preformed
C5b-6 with addition of purified C7, 1251 C8 and C9. The remaining
labeled C8 was found in a 9S fraction corresponding to the
position of the 125j C8 alone. In C— PVG sera no radioactivity was
seen in the 19S region, and all radioactivity appeared in the 9S
fraction. In C— PVG serum supplemented with human C6, 14%
of the radioactivity (74% of that in the C+ serum) was found in
the 19S fraction and the remainder in 9S. These data represent
the mean of two independent experiments.
Glomerular morphology
The results of light and immunofluorescence studies are sum-
marized in Table 2. By light microscopy there were no significant
differences in overall appearance between the three groups.
Intrinsic glomerular cell counts were not different between the
groups (Table 2). However, mesangiolysis was apparent in most
glomeruli by light and electron microscopy in C+ PVG rats but
was not detected in C— PVG rats or CVF treated rats (see below).
Glomerular cell proliferation was not present at day one but
was demonstrable at day five in C+ PVG animals. However,
proliferation was reduced by over 90% in C— and CVF treated
rats, confirming earlier studies which demonstrated that prolifer-
ation in this model is complement-dependent [11, 12]. Glomerular
cell proliferation was accompanied by a phenotypic change with
de novo expression of a-smooth muscle actin in C+ PVG rats as
reported previously in other strains [32]. No significant cx-actin
expression was seen in C— or CVF treated rats (Table 2).
Platelet infiltrates were also seen at day one in C+ PVG rats
but were markedly and equally reduced in C— and CVF treated
groups (Table 2, Fig. 1), also confirming the findings of previous
studies [11, 12].
Similarly, a prominent macrophage infiltrate was seen as early
as day one in C+ PVG rats but was markedly reduced in C— PVG
rats and was essentially abolished by CVF treatment (Table 2).
Finally, type IV collagen staining as an index of mesangial
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Fig. 1. Immunofluorescencephotomicrographs of representative glomemli at day 5 stained for goat JgG (top row), rat C3 (middle row) and rat C5b-9 (bottom
row). C+ PVG rats (left column) show 4+ staining for goat IgG, 3+ C3 and 2+ C5b-9. C— PVG rats (middle column) show staining for IgG and C3
similar to that in the C+ rats but no staining for C5b-9. CVF treated C+ rats (right column) show normal deposits of goat IgG but no staining for C3
or C5b-9. Original magnifications 400X.
matrix expansion was increased at day five in C+ PVG rats, as
previously reported in other strains [13]. Collagen IV staining was
substantially reduced in C— PVG rats and also by CVF treatment
(Table 2).
Immunofluorescence staining revealed prominent and equal
deposition of goat IgG in all three groups at day one (Table 2, Fig.
1). Rat C3d staining was equivalent in C+ and C— PVG rats but
was reduced by CVF treatment (Table 2). Quantitation of C3d IF
by confocal laser microscopy confirmed no significant reduction in
C3d staining in C— PVG rats compared to C+ controls (see
above). Rat C5b-9 staining was prominent at day five in C+ PVG
rats and was in a predominantly mesangial distribution (Table 2,
Figure 1). C5b-9 staining was absent in C— or CVF treated groups
(Table 2, Figure 1).
Ultrastructural studies
Electron microscopic studies of glomeruli from representative
animals in each group revealed changes similar to those described
in previous studies of the ATS model in other strains [4, 5]. In
contrast to the normal rat glomerulus, there were prominent
platelet infiltrates at day one in the C+ PVG animals (Fig. 2) as
well as a substantial amount of mesangiolysis (Fig. 3). Platelet
infiltration was markedly diminished on day one in C— PVG rats,
which exhibited no detectable mesangiolytic changes by electron
microscopy (Fig. 4).
Urine protein excretion
Proteinuria occurred on day one in C+ PVG rats (32 10
mg/day) and was substantially reduced in both C— PVG rats and
CVF treated animals (Table 2).
Discussion
Our findings demonstrate a marked reduction in severity of all
structural and functional consequences of glomerular injury in the
ATS model induced in C— PVG rats compared to C+ PVG
controls. The amelioration of disease in complement deficient
animals was comparable to that achieved by generalized comple-
ment depletion in C+ PVG rats induced by CVF and confirms
previous studies of the role of complement in this model [11, 12].
We believe the difference in disease manifestations between C+
and C— PVG rats is primarily due to the inability of C— rats to
form CSb-9 membrane attack complexes because of the total
absence of C6 in these animals. However, this contention requires
that the only significant difference between these groups be in the
ability to form C5b-9.
Leenaerts et al were the first to describe C6 deficiency in the
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Fig. 2. Electron micrograph of a C+ PVG rat glomerulus showing a focally
prominent influx of platelets one day after administration of A TS antiserum.
Magnification 11, 000x.
PVG rat utilizing animals obtained from the same source as the
C— PVG rats utilized in this study [331. Their studies document a
total lack of C6 inherited as an autosomal recessive trait. In
addition, Leenaerts et al report full reconstitution of CH50 activity
with purified human C6 and normal levels of individual rat
complement components C1—C7 (excluding C2), as well as normal
levels of factors D, B and H [33]. Others have confirmed a
deficiency or absence of C6 in other PVG strains [34, 35]. Finally,
Leenaerts et al reported these animals to be phenotypically and
immunologically normal with full acceptance of skin grafts be-
tween C— PVG and C+ PVG animals [33].
Our results confirm the total absence of C6 in C— PVG rats by
hemolytic assay, immunoblotting, and ELISA assays. We have
also demonstrated the inability of C— PVG rats to make detect-
able C5b-9 complexes following vigorous complement activation
in vitro or following antibody induced glomerular injury in vivo.
C5b-9 formation by C+ PVG rat controls in vivo was comparable
to that seen in other rat strains with normal CH50 levels. We also
found that individual complement components other than C6
were greater than 50% of values in C+ PVG animals except for
Fig. 3. Electron micrograph of a C+ PVG rat glomendus one day after
administration of A TS. There is marked mesangiolysis (M) with preserva-
tion of glomerular endothelium and capillary wall structures. Magnifica-
tion 10,000X.
C2 and CS, which were 15 and 20% of normal values, respectively.
With regard to a possible contribution of low C2 levels to our
results, the presence of equal amounts of C3d deposition in
glomeruli of C— and C+ PVG rats quantitated by confocal laser
microscopy in this and other studies of experimental membranous
nephropathy in C— PVG and C+ PVG rats (data not shown)
suggests that C3 activation in glomeruli was not limited by C2.
This conclusion would apply regardless of whether C3 activation
occurs via the classical pathway of complement activation where
reduced C2 might be limiting, or via the alternative pathway as
may occur with damaged cells in other settings [36, 37].
A larger concern would be that reduced CS levels led to
impaired generation of C5a in the C— PVG group. However,
measurements of C5a generation revealed no significant differ-
ences between C— and C+ PVG sera, and no neutrophils were
seen in either group confirming previous findings by ourselves and
others that neutrophils do not participate in the ATS lesion [4, 10,
11. Moreover, the observation that C— PVG serum supple-
mented with human C6 generated 74% of the CSb-9 complexes
generated by C+ PVG serum suggests that C5b-9 generation in
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Fig. 4. Electron micrograph of a C— PVG rat glomerulus one day after administration ofATS antiserum. Mesangiolysis and platelet infiltrates are absent.
Magnification 5600x.
the presence of C6 is normal in C— PVG rats. The fact that C5b-9
generation was not 100% of levels in C+ PVG rats probably
reflects the less efficient utilization of human C6 in generating
C5b-9 in rat serum compared to C+ PVG rats where all rat distal
complement components are present. Thus, we believe the ability
of C— PVG rats to generate normal amounts of C5a and near
normal amounts of C5b-9 when human C6 is provided suggests
that the principal difference between C— and C+ PVG rats with
regard to nephritogenesis lies in the absence of C6 in C— rats and
consequently the inability of these animals to generate C5b-9.
Previous studies utilizing generalized complement depletion
induced with CVF or administration of a soluble CR1 molecule
have documented that several features of the ATS model are
dependent on complement activation induced by the binding of
IgG antibody to the mesangial cell membrane [11, 12]. These
features include mesangiolysis, glomerular localization of plate-
lets and macrophages, mesangial cell proliferation and conse-
quent phenotypic changes including expression of s-smooth mus-
cle actin, PDGF, PDGF receptors and deposition of type IV
collagen [11—131. Each of these features studied (PDGF and
PDGF receptors were not studied) was also markedly reduced in
C— PVG rats compared to C+ controls, and in most cases the
differences observed were comparable to those induced by admin-
istration of CVF, suggesting that C5b-9 was not simply contribut-
ing to these phenomena but in fact accounts for most of the
complement-dependent features observed.
With regard to the mechanism of the C5b-9 effect in the ATS
model, several processes are probably involved. In lytic amounts,
C5b-9 can kill nucleated glomerular cells, a process which likely
accounts for the mesangial lysis in C+ PVG animals [15, 38]. Cell
lysis may also promote release of intracellular cytokines and
growth factors, such as bFGF, which has been shown to play a role
in early mesangial cell proliferation in the ATS model [6, 7].
However, nucleated cells are generally resistant to lysis by C5b-9.
Rather, they may exhibit features of cell activation in response to
sublytic C5b-9, leading to overproduction of several inflammatory
mediators that likely contribute to glomerular disease [15—17, 38].
Thus, sublytic C5b-9 can induce mesangial cells in vitro to increase
production of prostaglandins, oxidants, growth factors such IL-I
and IL-8, cytokines such as TNF and extracellular matrix compo-
nents (collagen IV, fibronectin) [15—17, 39, 40]. It is therefore
likely that C5b-9 attack on mesangial cells in vivo induced by
deposition of anti-Thy 1 antibody normally elicits most or all of
these responses which were greatly diminished or absent in C—
PVG rats.
In terms of the other specific effects observed in this study,
platelet localization is likely mediated by complement through
C3b (CR1) receptors present on rat (but not human) platelets,
and platelets may aggregate in response to local stimuli such as
collagen exposure in areas of antibody/complement mediated
tissue injury [41—45]. Documentation of a role of C5b-9 in this
process suggests that tissue injury may be more important than
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C3b receptors in determining platelet localization in vivo. Because
mesangial cell proliferation is related to platelets, the proliferative
phase of this lesion is generally a complement-dependent phe-
nomenon [11, 12]. In our study, cell proliferation was reduced by
80% in C— PVG rats and by over 90% in CVF treated C+ PVG
animals, suggesting that most of the complement effect on cell
proliferation is C5b-9 mediated. In addition to the platelet related
effects, C5b-9 may cause proliferation through a direct effect [46],
through mediating release of growth factors from lysed cells [6, 7],
or by stimulating release of growth factors such as IL-i directly
through sublytic effects [16].
Glomerular macrophage infiltration was also reduced in C—
PVG rats. Glomerular macrophage recruitment is also multifac-
tonal. Complement-derived chemotactic factors may recruit
monocyte/macrophages, macrophages exhibit C3b receptors, and
sublytic complement attack on glomerular cells may induce re-
lease of other molecules directly chemotactic for monocytes such
as IL-I, TNF and monocyte chemotactic peptide [reviewed in 39].
Moreover, complement mediated injury may lead to up-regula-
tion of leukocyte adherence molecules for monocytes and their
ligands such as ICAM-1 and LFA-1 [47]. Monocytes are not only
involved in mediating acute glomerular injury [48] but are also
potent sources of TGF/3, which has been established to mediate
matrix expansion and glomeruloscierosis in this model [8, 9]. It is
noteworthy that in C— PVG rats not only were a host of structural
lesions characteristic of the anti-Thy 1 model modified, but also
proteinuria was reduced by over 50%, demonstrating that the
cellular events described must also have important functional
consequences that were also dependent on CSb-9.
In summary, despite ample evidence for effects of sublytic
C5b-9 in mediating injury and activation of glomerular cells in
vitro, our study provides the first direct evidence that C5b-9
mediates several manifestations of glomerular injury in an inflam-
matory model of glomerulonephritis in vivo. C5b-9 dependent
phenomena included mesangiolysis, platelet localization, cell pro-
liferation, cell phenotype change, macrophage infiltration, matrix
expansion and proteinuria. These observations extend previous
studies which have documented a pathogenic role for C5b-9 only
in mediating changes in urinary protein excretion in non-inflam-
matory models of membranous nephropathy [49]. They also
provide several potential mechanisms for the postulated nephri-
togenic potential of CSb-9 in human glomerular diseases associ-
ated with mesangial cell proliferation [50, 51].
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